Search

Your search keyword '"Russcher, Anne"' showing total 12 results
Start Over Author "Russcher, Anne" Search Limiters Full Text
12 results on '"Russcher, Anne"'

2. Highly Divergent SARS-CoV-2 Alpha Variant in Chronically Infected Immunocompromised Person

Author

Munnink, Bas B. Oude, Nijhuis, Roel H.T., Worp, Nathalie, Boter, Marjan, Weller, Babette, Verstrepen, Babs E., GeurtsvanKessel, Corine, Corsten, Maarten L., Russcher, Anne, and Koopmans, Marion

Subjects
Immunocompromised host -- Case studies, Health
Abstract

Persons with an immune deficiency can be infected with viral pathogens for a prolonged period. This occurrence has been reported for noroviruses (1) but also has been documented for SARS-CoV-2 [...]

Published
2022
Full Text
View/download PDF

4. Highly Divergent SARS-CoV-2 Alpha Variant in Chronically Infected Immunocompromised Person

Author

Oude Munnink, Bas B., Nijhuis, Roel H.T., Worp, Nathalie, Boter, Marjan, Weller, Babette, Verstrepen, Babs E., GeurtsvanKessel, Corine, Corsten, Maarten L., Russcher, Anne, Koopmans, Marion, Oude Munnink, Bas B., Nijhuis, Roel H.T., Worp, Nathalie, Boter, Marjan, Weller, Babette, Verstrepen, Babs E., GeurtsvanKessel, Corine, Corsten, Maarten L., Russcher, Anne, and Koopmans, Marion

Abstract

We detected a highly divergent SARS-CoV-2 Alpha variant in an immunocompromised person several months after the latest detection of the Alpha variant in the Netherlands. The patient was infected for 42 weeks despite several treatment regimens and disappearance of most clinical symptoms. We identified several potential immune escape mutations in the spike protein.

Published
2022

6. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020

Author

Van Walle, Ivo, Leitmeyer, Katrin, Broberg, Eeva K, Van Esbroeck, Marjan, Beuselinck, Kurt, Vermeersch, Pieter, Karagiannis, Christos, Mentis, Andreas, Lampropoulou, Stavroula, Erlund, Iris, Melin, Merit, Ekström, Nina, Vihervaara, Terhi, Gaymard, Alexandre, Frobert, Emilie, Escuret, Vanessa, Kurolt, Ivan-Christian, Fournier, Guillaume, Abdelrahman, Tamir, Nguyen, Trung, Klak, Adrian, Bos, Anne E, Russcher, Anne, van ’t Veen, Annemarie, Stemerding, Annette M, van Corteveen-Splinter, Annette, van Hees, Babette C, Wintermans, Bas B, Herpers, Bjorn L, Reusken, Chantal BEM, van der Donk, Christel FM, Oliveira dos Santos, Claudy, GeurtsvanKessel, Corine H, Timmerman, Cornelis P, Ong, David SY, Kaersenhout, Deborah J, van Lochem, Ellen, Geeraedts, Felix, Rijkers, Ger T, Berkhout, Hannke, Koeleman, Hans GM, van Loo, Inge HM, Rahamat-Langendoen, Janette, Murk, Jean-Luc, Tjhie, Jeroen HT, Kissing, Johan, Reimerink, Johan, Kerremans, Jos J, de Vries, Jutte JC, Heemstra, Karen A, Thai, Khoa TD, Jim, Kin Ki, Mulder, Leontine, van den Beld, Maaike JC, Batstra, Manou R, Konstantinovski, Maria M, Wegdam-Blans, Marjolijn CA, Hoogewerf, Martine, de Graaf, Melanie J, de Jong, Menno D., Heron, Michiel, van Rijn, Michiel, Heusinkveld, Moniek, Van Burgel, Nathalie, Savelkoul, Paul HM, den Reijer, Paul Martijn, Wever, Peter C, Croughs, Peter, Zonneveld, Rens, van Gyseghem, Sim, Thijsen, Steven FT, Stoof, Susanne P, Jurriaans, Suzanne, Debast, Sylvia B, Mank, Theo, Hira, Vishal, Michalski, Aleksander, Siewierska-Puchlerska, Anna, Gajda, Ewa, Paciorek, Jarosław, Pakieła, Marta, Kołakowska-Kulesza, Agnieszka, Pancer, Katarzyna, Nowakowska, Magdalena, Costa, Inês, Zé-Zé, Líbia, Guiomar, Raquel, Hammas, Berit, Öckinger, Johan Brynedal, Prosenc, Katarina, and Berginc, Nataša

Subjects
Infecções Respiratórias, medicine.medical_specialty, Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), diagnostic, specificity, Sensitivity and Specificity, Gastroenterology, Asymptomatic, Nucleic Acids, Virology, Internal medicine, medicine, Humans, media_common.cataloged_instance, European union, Pandemics, media_common, Infecções Sistémicas e Zoonoses, accuracy, biology, SARS-CoV-2, business.industry, Research, Public Health, Environmental and Occupational Health, COVID-19, sensitivity, Confidence interval, meta-analysis, Study heterogeneity, Meta-analysis, biology.protein, Nucleic acid, Antibody Tests, Antibody, medicine.symptom, business
Abstract

Background Reliable testing for SARS-CoV-2 is key for the management of the COVID-19 pandemic. Aim We estimate diagnostic accuracy for nucleic acid and antibody tests 5 months into the COVID-19 pandemic, and compare with manufacturer-reported accuracy. Methods We reviewed the clinical performance of SARS-CoV-2 nucleic acid and antibody tests based on 93,757 test results from 151 published studies and 20,205 new test results from 12 countries in the European Union and European Economic Area (EU/EEA). Results Pooling the results and considering only results with 95% confidence interval width ≤ 5%, we found four nucleic acid tests, including one point-of-care test and three antibody tests, with a clinical sensitivity ≥ 95% for at least one target population (hospitalised, mild or asymptomatic, or unknown). Nine nucleic acid tests and 25 antibody tests, 12 of them point-of-care tests, had a clinical specificity of ≥ 98%. Three antibody tests achieved both thresholds. Evidence for nucleic acid point-of-care tests remains scarce at present, and sensitivity varied substantially. Study heterogeneity was low for eight of 14 sensitivity and 68 of 84 specificity results with confidence interval width ≤ 5%, and lower for nucleic acid tests than antibody tests. Manufacturer-reported clinical performance was significantly higher than independently assessed in 11 of 32 and four of 34 cases, respectively, for sensitivity and specificity, indicating a need for improvement in this area. Conclusion Continuous monitoring of clinical performance within more clearly defined target populations is needed.

Published
2021

12. Interlaboratory Collaboration for Optimized Screening for Urinary Tract Infection

Author

Russcher, Anne, Kusters, Elske, Wolterbeek, Ron, Kuijper, Ed J., Cobbaert, Christa M., and van der Beek, Martha T.

Abstract

ABSTRACTAs the majority of urine samples submitted for culture yields a negative result, rapid screening that accurately predicts culture outcome benefits clinicians by reducing the time to result and improves the efficiency of the microbiological laboratory. Automated urinalysis using the IRIS Diagnostics iQ200 Elite (iQ200) analyzer permits just such a fast and large-scale screening. We aimed to predict and thus to reduce negative cultures with a screening algorithm based on iQ200 urinalysis in a tertiary university hospital. In parallel, we evaluated the performance of the iQ200 screen compared to that of Gram stain for sample quality. We screened 1,442 samples submitted for bacterial culture using the iQ200 analyzer; of these samples, 357 (24.8%) had a positive culture result. We identified the absence of microorganisms in the iQ200 screen as the strongest solitary predictor for a negative culture, with a sensitivity of 90.5% (323/357). The algorithm was further improved by performing logistic regression on leukocyte counts, which gave a cutoff of 65 leukocytes/µl to obtain the desired sensitivity of >95% (95.2%; 95% confidence interval [CI], 92.5 to 97.0), a negative predictive value of 97.3% (95% CI, 95.7 to 98.3), and an anticipated culture workload reduction of 44% (95% CI, 41 to 46). Concordance between sample quality based on Gram stain and iQ200 screening was only 72%, which was probably a result of interobserver effect in evaluation of the Gram stain. In conclusion, in our setting, screening by iQ200 proved to be a safe and cost-effective means to provide faster culture results, and it has the added benefit of a more objective evaluation of sample quality.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results